Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Cowen and Company Health Care Conference in Boston on Monday, March 6, 2017 at 2:00 p.m. Eastern Time. The presentation w...
Mar 1, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2016.  "We expect 2017 to be a pivotal year as we transform from an R&D-focused company to a commercial organization as we anticipate...
Feb 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of additional data from EASE LID 2, its Phase 3 open-label, long-term safety and efficacy study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) in...
Feb 28, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) will present results from its Phase 2 proof-of-concept study of ADS-5102 (amantadine hydrochloride) extended-release capsules for the treatment of walking impairment in patients with multiple sclerosis (MS) at the Americas Committee for Treatment and ...
Feb 17, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016 achievements. "We expect 2017 to be a landmark year for Adamas," said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceutical...
Jan 8, 2017 General Releases HTML PDF
-- PDUFA Action Date Set for August 24, 2017 --  -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson's Disease -- EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accept...
Jan 6, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in development for the treatment of partial onset seizures in patients with epilepsy. Derived from the Company's development platform, ADS-4101 is chrono-s...
Jan 3, 2017 General Releases HTML PDF